CAJ | 학술논문

目的：观察贝伐单抗在恶性肿瘤治疗过程中的不良反应。方法：52例晚期恶性肿瘤患者，给予贝伐单抗7．5mg/（kg·3w），3周为1观察周期，5mg/（kg·2w），4周为1观察周期，单药或联合化疗，观察患者的主要不良反应。结果：52例患者共接受134周期治疗。主要不良反应为高血压（19．2％）、出血（13．5％）和蛋白尿（9．6％），其中3例发生血栓栓塞、1例发生严重心肌缺血不能耐受继续治疗。结论：贝伐单抗的主要不良反应为高血压、出血和蛋白尿，多为I-II级。不良反应发生率低，耐受性好。
목적：관찰패벌단항재악성종류치료과정중적불량반응。방법：52례만기악성종류환자，급여패벌단항7．5mg/（kg·3w），3주위1관찰주기，5mg/（kg·2w），4주위1관찰주기，단약혹연합화료，관찰환자적주요불량반응。결과：52례환자공접수134주기치료。주요불량반응위고혈압（19．2％）、출혈（13．5％）화단백뇨（9．6％），기중3례발생혈전전새、1례발생엄중심기결혈불능내수계속치료。결론：패벌단항적주요불량반응위고혈압、출혈화단백뇨，다위I-II급。불량반응발생솔저，내수성호。
Objective:To investigate the toxicities of bevacizumab.Methods:Total of 52 patients with advanced cancer were treated with bevacizumab 7.5mg/m2 or plus chemotherapy at intervals of 3 weeks.Results:All 52 pa-tients were treated with bevacizumab and totally 134 treatment cycles were completed.Hypertension(19.2%),pro-teinuria (13.5%)and bleeding (9.6%)were the main toxicities,3 patients with thrombotic infarct and 1 patient shuffered from myocardial ischemia could not be treated with bevacizumab again.Conclusion:Hypertension,proteinu-ria and bleeding were the main toxicities of bevacizumab,most were grade I and grade II,with low tox-side reaction, bevacizumab is well tolerated by the patients.